Proteomics: Improving biomarker translation to modern medicine?

Genome Medicine

Volumn 5, Issue 2, 2013, Pages

  Guest, Paul C ^a   Gottschalk, Michael G ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB;

DRUG TARGETING; EDITORIAL; GENOMICS; HUMAN; IMAGE ANALYSIS; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TRANSCRIPTOMICS; TREATMENT RESPONSE;

EID: 84874255998     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm421     Document Type: Editorial

References (11)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov 2006, 5:993-996. 10.1038/nrd2199, 17139284.
3. Sanz-Pamplona R, Berenguer A, Sole X, Cordero D, Crous-Bou M, Serra-Musach J, Guinó E, Ángel Pujana M, Moreno V. Tools for protein-protein interaction network analysis in cancer research. Clin Transl Oncol 2012, 14:3-14. 10.1007/s12094-012-0755-9, 22262713.
4. Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N, Yamada T. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol 2013, 43:103-109. 10.1093/jjco/hys200, 23248327.
5. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998, 52:65-77. 10.1023/A:1006111117877, 10066073.
6. Flood DG, Marek GJ, Williams M. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol 2011, 81:1422-1434. 10.1016/j.bcp.2011.01.021, 21295552.
7. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011, 76:280-286. 10.1212/WNL.0b013e318207b1b9, 3034393, 21178097.
8. Plymoth A, Hainaut P. Proteomics beyond proteomics: toward clinical applications. Curr Opin Oncol 2011, 23:77-82. 10.1097/CCO.0b013e32834179c1, 21107258.
9. Amayo AA, Kuria JG. Clinical application of tumour markers: a review. East Afr Med J 2009, 86(12 Suppl):S76-83.
10. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782. 10.2217/14622416.7.5.773, 16886901.
11. Khristov V. Glucose clamping-a modern method for research on insulin secretion and resistance. Vutr Boles 1986, 25:32-39.